<DOC>
	<DOCNO>NCT01528839</DOCNO>
	<brief_summary>There grow evidence thyroid axis dysfunction may contribute pathophysiology bipolar illness . Open-label study consistently demonstrate behavioral expression bipolar disorder modify change thyroid status , many instance course illness improve use adjunct thyroid hormone treatment . Recent evidence emerge acute intervention study add-on treatment supraphysiological dos levothyroxine effective augmenting agent patient major depressive episode . The primary goal international multicenter trial ( 5 site ) determine 13-week , randomize , placebo-controlled design ( 1 week single-blind placebo run-in , 6 week double-blind , 6 week open-label ) efficacy safety add-on treatment levothyroxine ( 300 mcg/d ) combination mood stabilizer/antidepressant therapy treatment patient bipolar depression . The main hypothesis : treatment levothyroxine result significantly great mean reduction HRSD total score high number responder remitters compare placebo treatment . This proposal build pilot data provide evidence use levothyroxine effective augmentation strategy treatment bipolar depression .</brief_summary>
	<brief_title>Supraphysiological Doses Levothyroxine Adjunctive Therapy Bipolar Depression</brief_title>
	<detailed_description />
	<mesh_term>Depression</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<criteria>Diagnosis bipolar I II disorder , currently depressive episode accord Diagnostic Statistical Manual Mental Disorders , Fourth Edition ( DSMIV ) Hamilton Rating Scale Depression ( HAMD ) 17item score ≥14 , HAMD item 1 ( depressed mood ) score ≥2 screen randomization visit Young Mania Rating Scale ( YMRS ) score ≤12 screen randomization visit . Pretreatment mood stabilizer and/or antidepressant standard dos ( Bauer et al . 2007a ) least six week since last dose adjustment , least two week enrollment Serum level mood stabilizer require within therapeutic range TSH level normal range ( serum TSH 0.3 4.7 mU/l ) Any axis I disorder bipolar disorder Recent ultrarapid cycling course ( 12 episode previous year ) , diagnosis substance dependence ( DSMIV ) substance use ( except nicotine ) within 12 month screen visit Clinically significant medical illness , especially severe cardiovascular disease Organic brain disorder Current serious suicidal homicidal risk clinical judgment investigator History previous current thyroid disease Thyroid hormone treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Bipolar disorder</keyword>
	<keyword>Bipolar depression</keyword>
	<keyword>Thyroid abnormality</keyword>
	<keyword>mood stabilizer</keyword>
	<keyword>antidepressant</keyword>
	<keyword>currently depress</keyword>
</DOC>